📝 Ajooni Biotech Limited — results explained
Quarter ended June 2026 (Q1 FY27)
Ajooni Biotech Limited reported revenue of ₹63 crore for the quarter ended June 2026 (Q1 FY27), up 103.0% from ₹31 crore in the same quarter last year, and up 4.7% sequentially over the March 2026 quarter.
Net profit fell 44.6% year-on-year to ₹0 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.01.
Operating profit stood at ₹2 crore — an operating margin (OPM) of 2.6%, compared with 2.3% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Ajooni Biotech Limited posted revenue of ₹182 crore, a growth of 59.0% over FY25, with a net profit of ₹4 crore (up 28.3% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹215 crore with a net profit of ₹4 crore.
Valuation snapshot
At the current price of ₹3.02, AJOONI has a market capitalisation of ₹52 crore and a trailing P/E of about 13.1.
Within the Food - Processing - Indian industry, it is the 25th-largest of the 40 companies we track by market value.
Shareholding pattern
As of Aug 2026, promoters held 30.53%, public shareholders 69.47% of Ajooni Biotech Limited.
Promoter holding rose from 26.89% to 30.53% over the latest period.